Holcomb KZ

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: May 2009.

Mr. Geria, Dr. Holcomb, and Dr. Scheinfeld report no conflict of interest. The authors discuss off-label use of interferon alfa, oral zinc sulfate, and ribavirin. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Mr. Geria is a medical student, New Jersey Medical School, Newark. Dr. Holcomb is staff dermatologist, National Capital Corsortium Residency Program, National Naval Medical Center, Bethesda, Maryland, and Walter Reed Army Medical Center, Washington, DC. Dr. Scheinfeld is Assistant Attending, St. Luke's-Roosevelt Hospital Center, New York, New York, and Assistant Clinical Professor of Dermatology, Columbia University, New York.

Aanand N. Geria, BS; Katherine Z. Holcomb, MD, MSPH; Noah S. Scheinfeld, MD, JD

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: May 2009.

Mr. Geria, Dr. Holcomb, and Dr. Scheinfeld report no conflict of interest. The authors discuss off-label use of interferon alfa, oral zinc sulfate, and ribavirin. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Mr. Geria is a medical student, New Jersey Medical School, Newark. Dr. Holcomb is staff dermatologist, National Capital Corsortium Residency Program, National Naval Medical Center, Bethesda, Maryland, and Walter Reed Army Medical Center, Washington, DC. Dr. Scheinfeld is Assistant Attending, St. Luke's-Roosevelt Hospital Center, New York, New York, and Assistant Clinical Professor of Dermatology, Columbia University, New York.

Aanand N. Geria, BS; Katherine Z. Holcomb, MD, MSPH; Noah S. Scheinfeld, MD, JD

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: May 2009.

Mr. Geria, Dr. Holcomb, and Dr. Scheinfeld report no conflict of interest. The authors discuss off-label use of interferon alfa, oral zinc sulfate, and ribavirin. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Mr. Geria is a medical student, New Jersey Medical School, Newark. Dr. Holcomb is staff dermatologist, National Capital Corsortium Residency Program, National Naval Medical Center, Bethesda, Maryland, and Walter Reed Army Medical Center, Washington, DC. Dr. Scheinfeld is Assistant Attending, St. Luke's-Roosevelt Hospital Center, New York, New York, and Assistant Clinical Professor of Dermatology, Columbia University, New York.

Aanand N. Geria, BS; Katherine Z. Holcomb, MD, MSPH; Noah S. Scheinfeld, MD, JD